To assess if endogenous KMT2D regulates the expression of endogenous GR in these cells, we used CRISPR/Cas9 to target KMT2D in L363 cells, a GC-sensitive multiple myeloma cell line (26). The gene discussed is NR3C1; the disease is plasma cell myeloma.